Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.420
+0.090 (2.08%)
Sep 15, 2026, 1:45 PM EDT - Market open
Immuneering Employees
Immuneering had 57 employees as of June 30, 2026. The number of employees increased by 3 or 5.56% compared to the same quarter last year.
Employees
57
Change
3
Growth
5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,004,846
Market Cap
285.96M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 57 | 3 | 5.56% |
| Mar 31, 2026 | 55 | 1 | 1.85% |
| Dec 31, 2025 | 53 | -1 | -1.85% |
| Sep 30, 2025 | 54 | -12 | -18.18% |
| Jun 30, 2025 | 54 | -12 | -18.18% |
| Mar 31, 2025 | 54 | -11 | -16.92% |
| Sep 30, 2024 | 66 | -1 | -1.49% |
| Jun 30, 2024 | 66 | 0 | - |
| Mar 31, 2024 | 65 | -3 | -4.41% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Sep 30, 2023 | 67 | -7 | -9.46% |
| Jun 30, 2023 | 66 | -8 | -10.81% |
| Mar 31, 2023 | 68 | 0 | - |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Sep 30, 2022 | 74 | 38 | 105.56% |
| Jun 30, 2022 | 74 | 40 | 117.65% |
| Mar 31, 2022 | 68 | 36 | 112.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Bicycle Therapeutics | 288 |
| Fate Therapeutics | 161 |
| Lyell Immunopharma | 161 |
| Sutro Biopharma | 128 |
| Lineage Cell Therapeutics | 77 |
| Pyxis Oncology | 56 |
| Camp4 Therapeutics | 48 |
IMRX News
- 21 hours ago - Immuneering Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 days ago - Immuneering Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 days ago - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival - GlobeNewsWire
- 11 days ago - Immuneering to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Immuneering says FDA approval of pancreatic cancer treatment ‘good news’ - TheFly
- 19 days ago - Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - GlobeNewsWire
- 5 weeks ago - Immuneering initiated with a Buy at H.C. Wainwright - TheFly
- 5 weeks ago - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire